e-ISSN: Pending
Replication FailureOpen accessPsychology· cited by 10

A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial

David Erritzøe; Tommaso Barba; Tiffanie Benway; Zelah Joel; Meghan Good; Marie Layzell; Michelle Baker Jones; Graham Campbell · 2026 · Nature Medicine

WASTE classifies this as Replication Failure · AI classification, approximate

A previously reported effect did not replicate here — verify it holds before you build on it.

Abstract

Major depressive disorder (MDD) is a leading cause of disability worldwide, yet many patients have inadequate responses to current treatments. Dimethyltryptamine (DMT), a serotonergic psychedelic with rapid onset and short duration, shows promise as a potential antidepressant (AD), although clinical evidence in MDD remains limited. We conducted a phase IIa, double-blind, placebo-controlled, randomized clinical trial to evaluate the efficacy and safety of intravenous DMT (SPL026; DMT fumarate) in adults with moderate-to-severe MDD. Participants received a single 21.5-mg dose of DMT or placebo i

Abstract by David Erritzøe; Tommaso Barba; Tiffanie Benway; Zelah Joel; Meghan Good; Marie Layzell; Michelle Baker Jones; Graham Campbell, Nature Medicine (2026) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1038/s41591-025-04154-z